Table 4.

Respiratory Outcomes for Liveborn Neonates According to Maternal Treatment Assignment

Outcome	Omega-3 (n=425)	Placebo (n=403)	Relative Risk (95% CI)
Respiratory distress syndrome	59 (13.9)	35 (8.7)	1.60 (1.08–2.37)
Received surfactant	38 (8.9)	29 (7.2)	1.24 (0.78–1.98)
Bronchopulmonary dysplasia	9 (2.1)	6 (1.5)	1.42 (0.51–3.96)
Transient tachypnea	31 (7.3)	24 (6.0)	1.22 (0.73–2.05)
Supplemental oxygen* (d)	2.2±8.9	1.9±9.4
Ventilator support† (d)	0.8±5.6	0.5±4.0

CI, confidence interval.

Data are n (%) or mean±standard deviation unless otherwise specified. Medians and interquartile ranges were all zero.

Respiratory distress syndrome (RDS) was defined as a clinical diagnosis of type I RDS and oxygen therapy (FiO₂ more than 0.40) for more than 24 hours or by death before 24 hours in a neonate who met the other criteria for RDS. Bronchopulmonary dysplasia was defined as the requirement for supplemental oxygen at 36 weeks corrected age for neonates born before 34 weeks. Transient tachypnea was defined as the requirement for supplemental oxygen with or without mechanical ventilation during the first 24 hours of life in a neonate in whom there were no other causes of respiratory distress.

^*P=.16.

^†P=.28.